logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
01-Sep-2018 To 30-Nov-2018
Mirati Therapeutics, Inc.
Update from phase Ib study of Sitravatinib as a single agent
Non-small cell lung cancer
01-Sep-2018 To 30-Nov-2018
Mirati Therapeutics, Inc.
Update from phase II study of Mocetinostat
Non-small cell lung cancer
after Q4 2018
Celsion Corp.
Clinical findings from Phase I cohort of 12 patients of Phase I/II randomized clinical trial of GEN-1 (OVATION II )
Localized treatment of ovarian cancer
Aug 2018
RedHill Biopharma Ltd.
Top-line results from Phase III study of RHB-104(MAP US study)
Crohn's disease
Aug 2018
Esperion Therapeutics
Top-line results from the pivotal Phase 3 Study (1002FDC-053) of the bempedoic acid / ezetimibe combination pill
ASCVD patients on maximally tolerated statin background therapy
2H 2018
Karyopharm Therapeutics Inc.
submission of NDA for oral Selinexor
Penta-refractory multiple myeloma
2H 2018
BioXcel Therapeutics, Inc.
Data readouts from phase IB trials of BXCL501
Geriatric dementia and schizophrenia/bipolar
2H 2018
MacroGenics Inc.
Updated data from phase I study of Flotetuzumab
Acute myeloid leukemia dose expansion cohort
2H 2018
MacroGenics Inc.
Submission of IND application for MGD019
To provide co-blockade of both PD-1 and CTLA-4 on T cells
Q3 2018
Pfenex Inc.
Submission of NDA for PF708
Osteoporosis
Q3 2018
Summit Therapeutics plc
Top-line 48-week data from phase II trial of Ezutromid (PhaseOut DMD study)
Duchenne muscular dystrophy
Q3 2018
Selecta Biosciences Inc.
Data from 5 doses phase II trial of SEL-212
Chronic severe gout
Q3 2018
Summit Therapeutics plc
48-week data from PhaseOut DMD trial of Ezutromid
Duchenne muscular dystrophy
2H 2018
RedHill Biopharma Ltd.
Top-line results from confirmatory Phase 3 study of TALICIA (ERADICATE Hp 2 study)
H. pylori infection
2H 2018
CymaBay Therapeutics Inc.
52-week data from phase II study of Seladelpar
Primary Biliary Cholangitis
2H 2018
uniQure N.V.
submission of IND for AMT-130
Huntington's disease
Q3 2018
Ovid Therapeutics Inc.
Topline data from phase 2 study of OV101 (STARS)
Angelman Syndrome
2H 2018
Ovid Therapeutics Inc.
Topline data from Phase 1b/2a trial of TAK-935/OV935
Adults with Rare Developmental and Epileptic Encephalopathies
2H 2018
resTORbio, Inc.
Data from phase IIb trial of RTB101
Respiratory tract infections (RTIs)
2H 2018
Ultragenyx Pharmaceutical Inc
Data from phase III study of Crysvita
Pediatric patients with X-linked hypophosphatemia (XLH)
2H 2018
Arcus Biosciences, Inc
Clinical activity data from Phase 1 dose-escalation trial of AB122
Cancer
2H 2018
Ultragenyx Pharmaceutical Inc
Data from phase III movement disorder study of UX007
Glucose transporter type-1 deficiency syndrome
2H 2018
Tracon Pharmaceuticals, Inc.
Data from Phase 1b trial of TRC105 in combination with Opdivo
Non-small cell lung cancer
2H 2018
Tracon Pharmaceuticals, Inc.
Interim analysis results from Phase 3 pivotal TAPPAS trial of TRC105
Angiosarcoma
2H 2018
Tracon Pharmaceuticals, Inc.
Top-line data from randomized Phase 2 TRAXAR trial of TRC105 in combination with Inlyta
Advanced or metastatic renal cell carcinoma